SCHEDULE: KALA BIO: David Lazar Takes 5.18% Stake, Resigns as CEO

David E. Lazar has acquired a 5.18% beneficial ownership in KALA BIO, Inc. through convertible preferred stock, was appointed CEO and board member, but subsequently resigned as CEO while remaining on the board.

Summary

• David E. Lazar acquired 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock in KALA BIO, Inc. for $1.8 million on November 23, 2025.
• These preferred shares are convertible into 49.5 million common shares, representing approximately 5.18% of KALA BIO's outstanding common stock.
• Lazar was appointed Chief Executive Officer and a member of the Board of Directors, effective November 23, 2025.
• He subsequently resigned as Chief Executive Officer on February 2, 2026, but remains a member of the Board of Directors.
• Lazar transferred his rights and obligations for 2,100,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock to a private investor on December 11, 2025.
• The Series AA Preferred Stock includes full ratchet protection in any subsequent offerings and the right to participate in future financing transactions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed signal. While a significant investment and board presence from a private investor can be positive, the very quick CEO resignation raises concerns about leadership stability and strategic alignment, overshadowing the initial investment.

Positives

• A significant investor, David E. Lazar, has taken a substantial 5.18% stake in KALA BIO, indicating a belief in the company's value.
• The investment of $1.8 million provides KALA BIO with additional capital.
• The Series AA Preferred Stock includes full ratchet protection, safeguarding Lazar's investment against dilution in future equity offerings.
• Lazar has the right to participate in subsequent financing transactions, potentially providing ongoing capital support.

Negatives

• David E. Lazar's rapid resignation as CEO, effective February 2, 2026, shortly after his appointment on November 23, 2025, could signal instability or disagreement within management.
• The transfer of Series AAA Preferred Stock rights to another investor suggests a partial divestment of the initial planned investment by Lazar.

Risks

• Potential for management instability due to the rapid CEO change.
• Future changes in Lazar's investment position, including potential sales of shares, could impact stock price.
• The need for stockholder approval to increase authorized common stock and convert preferred shares introduces a dependency.
• Compliance with Nasdaq Listing Rule 5640 for director nominations.

Future Outlook

David E. Lazar intends to continuously review his investment and may adjust his position in KALA BIO based on market conditions, the company's financial position, and other investment opportunities. He may also engage in discussions with management and stockholders regarding strategic changes, including capitalization, board structure, and potential business combinations.

Management Comments

• "The Reporting Person purchased the Shares pursuant to the SPA based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity."

Industry Context

StockSavvy.ai notes that significant insider investments, especially by individuals taking on leadership roles, often signal confidence in a company's future. However, the rapid resignation of a newly appointed CEO, even if they remain on the board, can raise questions about internal stability or strategic alignment, which is particularly scrutinized in the volatile biotechnology sector.

Comparison to Industry Standards

• The 5.18% stake by an individual investor is a notable position, often seen in activist investor scenarios or strategic long-term plays. For instance, Carl Icahn's initial stakes in companies like Xerox or Herbalife often started with similar or larger percentages, leading to significant corporate governance changes.
• The "full ratchet protection" on the Series AA Preferred Stock is a strong anti-dilution provision, more common in early-stage venture capital or distressed asset investments, indicating a protective stance by the investor against future equity raises at lower valuations. This is a more aggressive protection than typical broad-based weighted average anti-dilution found in standard preferred stock agreements.
• The rapid CEO change (appointment and resignation within months) is unusual for a public company and could be compared to situations like the short tenure of Marissa Mayer at Yahoo or the frequent leadership changes at struggling tech firms, often preceding further strategic shifts or divestitures.

Management Changes

Corporate Governance

Related Party Transactions

• The Securities Purchase Agreement (SPA) between KALA BIO, Inc. and David E. Lazar, who subsequently became CEO and a board member, involves the acquisition of preferred stock and board appointments.

Stakeholder Impact

• Shareholders: Potential for significant changes in corporate governance and strategic direction due to David E. Lazar's substantial stake and board presence. The rapid CEO change could introduce uncertainty.
• Management/Employees: Changes in leadership, particularly the CEO role, can impact morale, strategic focus, and operational stability.
• Creditors: The capital raise provides some cash, but the overall strategic direction and stability will influence credit risk.

Next Steps

• KALA BIO to hold a stockholder meeting to approve an increase in authorized common stock and the conversion of Series AA Preferred Stock.
• KALA BIO to elect certain directors to its board of directors as per the SPA.
• David E. Lazar may recommend up to eight individuals for election at the upcoming stockholder meeting.
• David E. Lazar will continue to review his investment and may adjust his position or engage in further strategic discussions.

Key Dates

Recommendation

While the significant investment by David E. Lazar and his continued board presence suggest potential for future value, his rapid resignation as CEO creates uncertainty regarding leadership stability and strategic direction. The full ratchet protection is a positive for Lazar, but the overall situation presents mixed signals, warranting a 'hold' until more clarity emerges on the company's strategic path and stable leadership.

Keywords

KALA BIO, KALA, David Lazar, Schedule 13D, Preferred Stock, Convertible Securities, CEO Resignation, Board of Directors, Shareholder Activism, Investment, Biotechnology